Monday, November 6, 2017

Platelet Rich Plasma vs Hyaluronate for Ankle Pain in addition to Disability

Am J Sports Med. 2012 January 17. 

Platelet-Rich Plasma or Hyaluronate inwards the Management of Osteochondral Lesions of the Talus.

Source

Department of Orthopedic Surgery, Meir University Hospital, Kfar-Saba, Israel.

Abstract

BACKGROUND:

Nonoperative options for osteochondral lesions (OCLs) of the talar dome are limited, as well as currently, at that topographic point is a lack of scientific evidence to lead management.

PURPOSE:

To evaluate the short-term efficacy as well as security of platelet-rich plasma (PRP) compared amongst hyaluronic acid (HA) inwards reducing hurting as well as disability caused past times OCLs of the ankle.

STUDY DESIGN:

Randomized controlled trial; Level of evidence, 2.

METHODS:

Thirty-two patients aged xviii to threescore years were allocated to a handling past times intra-articular injections of either HA (group 1) or PRP (plasmarich in growth factors [PRGF] technique, grouping 2) for OCLs of the talus. Thirty OCLs, xv per arm, received 3 consecutive intra-articular therapeutic injections as well as were followed for 28 weeks. The efficacy of the injections inwards reducing hurting as well as improving business office was assessed at each take in using the American Orthopaedic Foot as well as Ankle Society (AOFAS) Ankle-Hindfoot Scale (AHFS); a visual analog scale (VAS) for pain, stiffness, as well as function; as well as the subjective global business office score.

RESULTS:

The bulk of patients were men (n = 23; 79%). The AHFS grade improved from 66 as well as 68 to 78 as well as 92 inwards groups i as well as 2, respectively, from baseline to calendar week 28 (P < .0001), favoring PRP (P < .05). Mean VAS scores (1 = asymptomatic, 10 = severe symptoms) decreased for hurting (group 1: 5.6 to 3.1; grouping 2: 4.1 to 0.9), stiffness (group 1: 5.1 to 2.9; grouping 2: 5.0 to 0.8), as well as business office (group 1: 5.8 to 3.5; grouping 2: 4.7 to 0.8) from baseline to calendar week 28 (P < .0001), favoring PRP (P < .05 for stiffness, P < .01 for function, P > .05 for pain). Subjective global business office scores, reported on a scale from 0 to 100 (with 100 representing healthy, preinjury function) improved from 56 as well as 58 at baseline to 73 as well as 91 past times calendar week 28 for groups i as well as 2, respectively (P < .01 inwards favor of PRP).

CONCLUSION:

Osteochondral lesions of the talocrural articulation treated amongst intra-articular injections of PRP as well as HA resulted inwards a decrease inwards hurting scores as well as an growth inwards business office for at to the lowest degree half-dozen months, amongst minimal adverse events. Platelet-rich plasma treatment led to a significantly improve lawsuit than HA.

Interesting novel data.

AM

Sumber http://plateletrichplasma.blogspot.com

No comments:

Post a Comment

Up